Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

Author's Avatar
May 25, 2022

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will host a key opinion leader (KOL) webinar about TNX-201 (oral, modified release imatinib), in development as a potential treatment for pulmonary arterial hypertension (PAH), on Thursday, June 2, 2022 at 11:00am Eastern Time.